Amiodarone

Pacerone: adult documented life-threatening recurrent VF and recurrent hemodynamically unstable ventricular tachycardia after adequate alternative antiarrhythmics fail or are not tolerated. IV products: initiation/prophylaxis of frequently recurring VF and hemodynamically unstable VT refractory to other therapy. These labels do not confer broad FDA approval for all atrial arrhythmias.

The 2023 AF guideline supports selected long-term sinus-rhythm maintenance, including HFrEF; in normal LV function, low-dose oral 100–200 mg/day is reserved when other strategies fail, are not preferred or are contraindicated. This is an off-label specialist decision, not the ventricular label loading/maintenance regimen. AHA 2025 cardiac-arrest algorithm separately places amiodarone in refractory VF/pulseless VT; it is not a routine rapid bolus for a perfusing patient.

Pacerone: 800–1,600 mg/day until initial response, usually 1–3 weeks; after control or prominent adverse effects reduce to 600–800 mg/day for 1 month, then usual maintenance 400 mg/day. Individualize to the lowest effective dose. Take consistently relative to meals; divide with meals at total daily doses ≥ 1,000 mg or GI intolerance. Skip a missed dose and take the next scheduled dose; never double.

Initial 150 mg over 10 minutes, then 1 mg/min for 6 hours (360 mg), then 0.5 mg/min for 18 hours (540 mg). After 24 hours usual 0.5 mg/min (720 mg/day); recurrent VF/unstable VT can receive 150 mg over 10 minutes. Mean daily doses > 2,100 mg increased hypotension in trials; selected concentrate also states initial infusion rate must not exceed 30 mg/min. These are monitored infusion directions, not a universal arrest bolus.

Nexterone: 150 mg/100 mL (1.5 mg/mL) and 360 mg/200 mL (1.8 mg/mL), ready to use; no further dilution or added medicines. Concentrate: 50 mg/mL, requires the full label’s D5W dilution and volumetric pump method; e.g.150 mg in 100 mL D5W over 10 minutes and 900 mg in 500 mL D5W for subsequent 1.8 mg/mL infusion. Use an in-line filter and dedicated central access when possible; concentrate infusions > 1 hour require central access if > 2 mg/mL. Check the exact admixture/line incompatibility and container instructions; do not transfer premix handling to concentrate.

Suggested initial oral daily doses after a 0.5 mg/min (720 mg/day) infusion: duration < 1 week 800–1,600 mg;1–3 weeks 600–800 mg;> 3 weeks 400 mg. This is a supervised transition based on accumulated IV exposure and oral bioavailability, not mg-for-mg route substitution; IV therapy is not intended for chronic maintenance.

AHA 2025 refractory VF/pulseless-VT arrest algorithm: first 300 mg IV/IO bolus, second 150 mg, in the CPR/defibrillation algorithm. Do not apply this rapid dose to a patient with a pulse. The AF guideline’s selected 100–200 mg/day oral maintenance concerns chronic off-label rhythm control, not an autonomous initiation/loading prescription; anticoagulation/stroke prevention is assessed separately.

Oral: cardiogenic shock; sick-sinus syndrome, second/third AV block or bradycardia causing syncope without a functioning pacemaker; hypersensitivity to amiodarone/components including iodine. IV: cardiogenic shock, marked sinus bradycardia, second/third AV block unless a functioning pacemaker is available, and product-component allergy including iodine. Evaluate the exact route’s wording rather than treating all bradycardia restrictions as identical.

Pacerone oral tablets have a boxed warning for pulmonary, hepatic and cardiac toxicity and restricted life-threatening-arrhythmia use with monitored initiation. The selected IV labels have no boxed warning; hypotension, proarrhythmia, acute hepatic/pulmonary injury and other serious risks still apply.

Oral experience includes nausea/vomiting, constipation, fatigue/tremor/ataxia, thyroid dysfunction, liver-test changes, photosensitivity, visual changes and pulmonary injury. IV reactions include hypotension, bradycardia/AV block, cardiac arrest/shock, abnormal liver tests and infusion injury/phlebitis. Postmarketing serious skin, blood, neurologic and organ reports do not define incidence. Overdose can cause lethal hypotension/shock, bradycardia/block and hepatic injury: urgent rhythm/BP monitoring and specialist support/pacing may be needed. Neither amiodarone nor DEA is dialyzable.

Avoid other QT-prolonging agents and grapefruit/inhibitors that markedly increase exposure; review St John’s wort/inducers that lower exposure. Beta blockers, verapamil/diltiazem, digoxin and other negative chronotropes increase bradycardia/block. Selected labels advise reducing digoxin by half or stopping, and reducing warfarin by one-third to one-half with close INR review; do not make these changes without the prescribing team. Simvastatin maximum 20 mg/day and lovastatin 40 mg/day with amiodarone. Monitor cyclosporine/renal function and phenytoin concentrations. Sofosbuvir-containing treatment has caused serious bradyarrhythmia; avoid/review with specialists and monitor if unavoidable. Other antiarrhythmics need reduced initiation and ECG surveillance; check the exact full interaction table.

Amiodarone/DEA cross placenta and can cause fetal/neonatal thyroid, cardiac, growth and neurodevelopmental harm. Untreated life-threatening maternal arrhythmia also poses risk; specialist benefit/risk assessment and neonatal thyroid/rhythm monitoring are needed. Breastfeeding is not recommended during therapy; substantial variable milk exposure and long tissue persistence require an individualized feeding plan. Animal studies suggest reduced fertility; human reversibility is unknown.

Safety/effectiveness of selected products are not established in children; no routine pediatric label regimen is supplied. Selected benzyl-alcohol concentrate particularly warns about neonatal gasping syndrome. Older adults have lower clearance/longer half-life and more comorbidity/co-therapy; cautious lower-end selection and clinical monitoring are appropriate.

Renal impairment does not materially affect amiodarone/DEA PK; no standard renal dose adjustment is defined. Hepatic disease needs close assessment and LFT monitoring. Oral label: reduce/stop if transaminases exceed 3 times normal or double from an elevated baseline; stop for clinical liver injury. IV progressive hepatic injury can require reducing infusion rate or withdrawing therapy. Do not invent a universal cirrhosis-dose percentage.

Usually classified class III, with characteristics of all four Vaughan Williams classes; prolongs action potential/refractoriness and slows nodal conduction. Oral bioavailability about 50%, peak 3–7 hours and protein binding about 96%; food increases exposure, so take consistently. CYP3A and CYP2C8 form DEA; hepatic/biliary elimination predominates and urinary parent-drug excretion is negligible. Oral single-dose terminal half-life ranged 15–142 days (DEA 14–75); IV studies give different ranges. Clinical effects/interactions can persist weeks to months. Serum concentrations have no universally established efficacy relationship; clinical rhythm/tolerability guide individualized dosing.

For labeled oral therapy: baseline ECG/electrolytes, chest film/PFTs, thyroid and aminotransferases; periodic thyroid/LFTs and label chest-film/exam every 3–6 months, plus ophthalmic surveillance. IV requires continuous ECG/QT, pulse/BP, infusion-site, electrolytes and organ-injury assessment. AF guideline table 24 separately suggests thyroid/LFT follow-up 3–6 months then every 6 months, annual ECG and symptom-triggered chest/eye assessment; it questions routine lung-test screening sensitivity. Document which plan the specialist uses rather than silently erase label precautions. Check INR/digoxin and device thresholds when relevant.

Take the exact oral dose consistently with meals and skip rather than double missed doses. Avoid grapefruit/St John’s wort and review all new medicines, including after stopping. Report new cough/dyspnea, fainting/palpitations, visual or thyroid symptoms, jaundice, severe rash or neuropathy promptly. Use sun protection; tell anesthesia staff and the device clinic about therapy. Do not independently discontinue a life-threatening-arrhythmia prescription; arrange urgent clinician-directed assessment. Discuss pregnancy and feeding plans.

Pacerone 200 mg pink round scored tablet, P 200 on unscored side and U-S /0147 across reverse score; NDC 0245-0147-60, 60-tablet bottle. Verify exact package/strength; not evidence of local stock.

Pacerone 100,200 and 400 mg tablets; Nexterone ready-to-use 150 mg/100 mL and 360 mg/200 mL IV bags; selected concentrate 50 mg/mL in 3,9 and 18 mL single-use vials. Concentrate contains benzyl alcohol/polysorbate 80; Nexterone formulation differs. Current selected FDA applications list Prescription products. Do not substitute volumes, bag preparation or pediatric excipient assumptions across formulations.

Oral: 20–25°C, excursions 15–30°C, tight light-resistant child-resistant container. Nexterone: 20–25°C, excursions 15–30°C, protect light/heat/freezing, retain carton until use, no added medicines; discard unused single-dose solution. Concentrate: 20–25°C, protect light/excessive heat, retain carton and discard unused portion; full label defines diluted-solution container/stability limits. Never use a compromised/leaking bag or particulate/discolored solution.